6 unchanged sentences
The complaint asserts claims for alleged breaches of fiduciary duty and unjust enrichment arising
−Removed: out of our dissemination of purportedly false and misleading statements relating to the filing of the New Drug Application (“NDA”)
+Added: out of our dissemination of purportedly false and misleading statements relating to the filing of the New Drug Application (“NDA”)
The relief sought in the complaint includes unspecified damages, changes to our corporate governance procedures, equitable
−Removed: and/or injunctive relief, restitution, and attorneys’
+Added: and/or injunctive relief, restitution, and attorneys’ fees.
On August 16, 2019, defendants filed a motion to dismiss
the complaint.
−Removed: In response, the plaintiff’s filed an amended stockholder derivative complaint.
−Removed: Defendants’
+Added: In response, the plaintiff’s filed an amended stockholder derivative complaint.
+Added: Defendants’ motion to
dismiss the amended complaint was filed on December 12, 2019;
−Removed: plaintiff’s response was filed on January 27, 2020 and defendants’
+Added: plaintiff’s response was filed on January 27, 2020 and defendants’
reply was filed on February 26, 2020.
2 unchanged sentences
court entered an order dismissing the complaint in its entirety.
−Removed: April 2, 2019, we filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging
−Removed: that Clarus’s JATENZO®
−Removed: product infringes six of Lipocine’s issued U.S.
+Added: On April 2, 2019, we filed a lawsuit against
+Added: Clarus in the United States District Court for the District of Delaware alleging that Clarus’s JATENZO®
+Added: product infringes
+Added: six of Lipocine’s issued U.S.
and 6,923,988.
−Removed: Clarus has answered the complaint and asserted counterclaims of non-infringement and invalidity.
−Removed: We answered Clarus’s counterclaims on April 29, 2019.
−Removed: The Court held a scheduling conference on August 15, 2019, a claim
−Removed: construction hearing on February 11, 2020 and scheduled a five-day jury trial beginning on February 8, 2021.
−Removed: On February 11, 2020,
−Removed: we voluntarily dismissed allegations of patent infringement for expired U.S.
−Removed: 6,569,463 and 6,923,988 in an effort to
−Removed: streamline the issues and associated costs for dispute.
−Removed: The parties are currently engaged in the fact discovery phase of the lawsuit.
+Added: Clarus has answered
+Added: the complaint and asserted counterclaims of non-infringement and invalidity.
+Added: We answered Clarus’s counterclaims on
+Added: April 29, 2019.
+Added: The Court held a scheduling conference on August 15, 2019, a claim construction hearing on February 11, 2020 and
+Added: scheduled a five-day jury trial beginning on February 8, 2021.
+Added: On February 11, 2020, we voluntarily dismissed allegations of patent
+Added: infringement for expired U.S.
+Added: 6,569,463 and 6,923,988 in an effort to streamline the issues and associated costs for
+Added: The parties are currently engaged in the fact discovery and expert testimony phase of the lawsuit.
On November 14, 2019, the Company
3 unchanged sentences
defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to the FDA contained
−Removed: deficiencies and as a result the defendants’
−Removed: statements about our business and operations were false and misleading and/or
+Added: deficiencies and as a result the defendants’ statements about our business and operations were false and misleading and/or
lacked a reasonable basis in violation of federal securities laws.
The lawsuit seeks certification as a class action (for a purported
−Removed: class of purchasers of the Company’s securities from March 27, 2019 through November 8, 2019), compensatory damages in an
+Added: class of purchasers of the Company’s securities from March 27, 2019 through November 8, 2019), compensatory damages in an
unspecified amount, and unspecified equitable or injunctive relief.
3 unchanged sentences
We filed a motion to dismiss this class action lawsuit on July 24, 2020.
+Added: In response, the plaintiff’s filed their response to the motion to dismiss the class action lawsuit on September 22, 2020.
Further, we intend to vigorously defend ourselves and our current and former officers and directors against these allegations and
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.